FULCRUM THERAPEUTICS INC (FULC)
US3596161097 - Common Stock
We assign a fundamental rating of 3 out of 10 to FULC. FULC was compared to 193 industry peers in the Pharmaceuticals industry. No worries on liquidiy or solvency for FULC as it has an excellent financial health rating, but there are worries on the profitability. While showing a medium growth rate, FULC is valued expensive at the moment.
1. Profitability
1.1 Basic Checks
FULC had negative earnings in the past year.
In the past year FULC has reported a negative cash flow from operations.
In the past 5 years FULC always reported negative net income.
FULC had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
FULC has a better Return On Assets (-6.42%) than 75.39% of its industry peers.
The Return On Equity of FULC (-6.96%) is better than 79.58% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -6.42% | ||
| ROE | -6.96% | ||
| ROIC | N/A |
ROA(3y)-40.21%
ROA(5y)-51.33%
ROE(3y)-44.95%
ROE(5y)-62.45%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
FULC does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
FULC does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for FULC has been increased compared to 1 year ago.
Compared to 5 years ago, FULC has more shares outstanding
FULC has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
FULC has an Altman-Z score of 4.52. This indicates that FULC is financially healthy and has little risk of bankruptcy at the moment.
FULC has a better Altman-Z score (4.52) than 80.10% of its industry peers.
FULC has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 4.52 |
ROIC/WACCN/A
WACC9.6%
2.3 Liquidity
FULC has a Current Ratio of 18.44. This indicates that FULC is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 18.44, FULC belongs to the top of the industry, outperforming 90.58% of the companies in the same industry.
FULC has a Quick Ratio of 18.44. This indicates that FULC is financially healthy and has no problem in meeting its short term obligations.
FULC's Quick ratio of 18.44 is amongst the best of the industry. FULC outperforms 90.58% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 18.44 | ||
| Quick Ratio | 18.44 |
3. Growth
3.1 Past
FULC shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 81.55%, which is quite impressive.
Looking at the last year, FULC shows a very strong growth in Revenue. The Revenue has grown by 2974.94%.
FULC shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -31.74% yearly.
EPS 1Y (TTM)81.55%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%10.26%
Revenue 1Y (TTM)2974.94%
Revenue growth 3Y-31.74%
Revenue growth 5YN/A
Sales Q2Q%-100%
3.2 Future
The Earnings Per Share is expected to grow by 7.49% on average over the next years.
FULC is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 15.96% yearly.
EPS Next Y84.67%
EPS Next 2Y9.49%
EPS Next 3Y3.68%
EPS Next 5Y7.49%
Revenue Next Year3363.89%
Revenue Next 2Y-41.42%
Revenue Next 3Y165.73%
Revenue Next 5Y15.96%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for FULC. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for FULC. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y9.49%
EPS Next 3Y3.68%
5. Dividend
5.1 Amount
FULC does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
FULCRUM THERAPEUTICS INC
NASDAQ:FULC (12/20/2024, 8:13:40 PM)
After market: 4.35 0 (0%)4.35
+0.32 (+7.94%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners103.3%
Inst Owner Change-13.73%
Ins Owners8.8%
Ins Owner Change3.16%
Market Cap234.64M
Analysts72.86
Price Target5.39 (23.91%)
Short Float %8.66%
Short Ratio5.84
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)3469.46%
Min EPS beat(2)15.39%
Max EPS beat(2)6923.53%
EPS beat(4)4
Avg EPS beat(4)1737.61%
Min EPS beat(4)3.64%
Max EPS beat(4)6923.53%
EPS beat(8)7
Avg EPS beat(8)873.81%
EPS beat(12)9
Avg EPS beat(12)583.94%
EPS beat(16)13
Avg EPS beat(16)441.22%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-67.19%
EPS NQ rev (1m)30.51%
EPS NQ rev (3m)30.51%
EPS NY rev (1m)14.84%
EPS NY rev (3m)37.5%
Revenue NQ rev (1m)-100%
Revenue NQ rev (3m)-100%
Revenue NY rev (1m)-0.05%
Revenue NY rev (3m)-8.09%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 2.9 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 0.91 | ||
| P/tB | 0.91 | ||
| EV/EBITDA | N/A |
EPS(TTM)-0.31
EYN/A
EPS(NY)-1.27
Fwd EYN/A
FCF(TTM)-0.16
FCFYN/A
OCF(TTM)-0.16
OCFYN/A
SpS1.5
BVpS4.77
TBVpS4.77
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -6.42% | ||
| ROE | -6.96% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)-40.21%
ROA(5y)-51.33%
ROE(3y)-44.95%
ROE(5y)-62.45%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.29
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 7.2% | ||
| Cap/Sales | 0.15% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 18.44 | ||
| Quick Ratio | 18.44 | ||
| Altman-Z | 4.52 |
F-Score5
WACC9.6%
ROIC/WACCN/A
Cap/Depr(3y)57.52%
Cap/Depr(5y)54.07%
Cap/Sales(3y)19.32%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)81.55%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%10.26%
EPS Next Y84.67%
EPS Next 2Y9.49%
EPS Next 3Y3.68%
EPS Next 5Y7.49%
Revenue 1Y (TTM)2974.94%
Revenue growth 3Y-31.74%
Revenue growth 5YN/A
Sales Q2Q%-100%
Revenue Next Year3363.89%
Revenue Next 2Y-41.42%
Revenue Next 3Y165.73%
Revenue Next 5Y15.96%
EBIT growth 1Y74.34%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year82.35%
EBIT Next 3Y12.61%
EBIT Next 5YN/A
FCF growth 1Y91.4%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y91.32%
OCF growth 3YN/A
OCF growth 5YN/A